Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. (Q54200563)

26 May 2018

review article

1 reference

title

Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. (English)

1 reference

26 May 2018

main subject

piperacillin/tazobactam

1 reference

P Charbonneau

1

1 reference

26 May 2018

publication date

1 July 1994

1 reference

26 May 2018

published in

Intensive Care Medicine

1 reference

26 May 2018

volume

20 Suppl 3

1 reference

26 May 2018

page(s)

S43-8

1 reference

26 May 2018

https://scigraph.springernature.com/pub.10.1007/bf01745251

exact match

0 references

cites work

Clavulanic Acid, a Novel Inhibitor of β-Lactamases

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Early synergistic interaction between semisynthetic penicillins and aminoglycosidic aminocyclitols against Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01745251

Therapy of soft tissue infections with piperacillin/tazobactam

21 January 2018

1 reference

12 December 2020

Penetration of piperacillin into bronchial mucosa and sputum

1 reference

12 December 2020

Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

1 reference

12 December 2020

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study

1 reference

12 December 2020

Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis

1 reference

12 December 2020

Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections

1 reference

12 December 2020

The frequency of bacterial pathogens in infections potentially preventable by antimicrobial prophylaxis.

1 reference

12 December 2020

Evolution of beta-lactamase inhibitors

1 reference

12 December 2020

1 reference

12 December 2020

Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria

1 reference

12 December 2020

In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases

1 reference

12 December 2020

Antimicrobial resistance: implications for antibiotic use.

1 reference

12 December 2020

The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia

1 reference

12 December 2020

Carbapenems: special properties contributing to their activity.

1 reference

12 December 2020

Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.

1 reference

12 December 2020

[Epidemiologic study of pathogens causing nosocomial infections]

1 reference

12 December 2020

A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital

1 reference

12 December 2020

Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors

1 reference

12 December 2020

New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases

1 reference

12 December 2020

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01745251

1 reference

26 May 2018

1 reference

26 May 2018